(Q72504482)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6117565%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

title

Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6117565%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

author name string

C Fischer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6117565%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

K Maier

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6117565%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

U Klotz

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6117565%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

publication date

1 October 1981

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6117565%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

volume

225

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6117565%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6117565%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

page(s)

498-503

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6117565%20AND%20SRC:MED&resulttype=core&format=json

An experiment to determine the active therapeutic moiety of sulphasalazine

27 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

Drug therapy: Sulfasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

Clinical Pharmacokinetics of Sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

Is Plasma Level Monitoring of Sulfasalazine Indicated in the Treatment of Crohnʼs Disease or Ulcerative Colitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4347%2800%2980303-5

7 January 2021

10.1016/S0378-4347(00)80303-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6117565%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

1 reference